Advertisement
Document › Details
Selexis S.A.. (6/20/19). "Press Release: Avacta and Selexis Partner to Develop Cell Line for Clinical Manufacturing". Cambridge & Geneva.
Avacta’s first Affimer clinical candidate is a potent PD-L1 antagonist under development for solid tumour indications as the basis of bispecific and combination therapies
Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and research reagents, and Selexis, a pioneering life sciences company and global leader in mammalian cell line generation technology, have partnered to develop the Chinese hamster ovary (CHO) cell line that will be used to manufacture Avacta’s first Affimer clinical candidate for first-time-in-human clinical trials. This major milestone means that Avacta remains on track to submit an IND/CTA application for an Affimer PD-L1 inhibitor by the end of 2020.
Avacta’s first clinical candidate will be against PD-L1, a clinically validated immune checkpoint that plays an important role in the tumour escape mechanism in cancer. The lead molecule (AVA004) is a potent PD-L1 antagonist that has been engineered with an Fc domain for half-life extension. Avacta has demonstrated the preclinical efficacy of AVA004 in syngeneic and xenograft mouse models and it compares favourably to approved monoclonal antibodies such as Imfinzi®, Tecentriq® and Bavencio® at the doses administered.
Alastair Smith, Avacta Group Chief Executive Officer, commented:
“The strategic partnership with Selexis allows Avacta to access the technology and know-how to develop high-expressing CHO cell lines as well as the extensive experience of developing a range of Fc fusion proteins for clinical manufacturing. These cell lines are the essential basis of clinical manufacturing of AVA004 and this partnership supports Avacta’s strategy to demonstrate safety and tolerability of the Affimer platform in humans with a planned IND/CTA by the end of 2020.
The ultimate aim is to combine AVA004 with other Affimer checkpoint modulators in bispecific cancer immunotherapies, and with novel chemotherapies as drug conjugates and combination therapies utilising proprietary tumour microenvironment targeting chemistry. These approaches seek to combine modulation of the adaptive immune response with stimulation of the innate immune system, with the aim of improving the clinical outcome for the sizeable proportion of solid tumour patients having “cold” tumours that do not respond to checkpoint inhibitors alone.”
Marco Bocci, PhD, Dpharm, Selexis Senior Vice President, Licensing and Business Development commented:
“Our agreement with Avacta is a result of Selexis’ leadership in bringing an innovative technology solution to our partners and the capability to enhance speed in drug development, including for those developing therapeutics that are beyond traditional monoclonal antibodies. It is rewarding for us to play a role as Avacta prepares to advance its first Affimer clinical candidate into the clinic.”
– Ends –
For further information from Avacta Group plc, please contact:
Avacta Group plc
Alastair Smith, Chief Executive Officer
Tony Gardiner, Chief Financial Officer
Tel: +44 (0) 844 414 0452
www.avacta.com
finnCap Ltd (Nominated Adviser and Joint Broker)
Geoff Nash / Giles Rolls – Corporate Finance
Tim Redfern – ECM
www.finncap.com
Tel: +44 (0) 203 705 9318
WG Partners (Joint Broker)
Nigel Birks / Nigel Barnes
David Wilson / Claes Spang
Tel: +44 (0) 207 220 0500
Tel: +44 (0) 203 705 9217
www.wgpartners.co.uk
Turner Pope Investments
James Pope / Ben Turner
Tel: +44 (0) 203 621 4120
www.turnerpope.com
Yellow Jersey PR (Financial Media and IR)
Sarah Hollins
Harriet Jackson
Tel: +44 (0)7764 947 137
Tel: +44 (0)7544 275 882
[email protected]
Zyme Communications (Trade and Regional Media)
Katie Odgaard
Tel: +44 (0)7787 502 947
[email protected]
For further information from Selexis SA, please contact:
Selexis (Company Enquiries)
Robert Meister- Head, Corporate Communications
Tel: +1 602-953-1716
Sam Brown Inc. (Media Enquiries)
Kelly Conlon
Tel: +1 207-233-2430
[email protected]
About Avacta Group plc – www.avacta.com
Avacta’s principal focus is on its proprietary Affimer® technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development.
Antibodies dominate markets worth in excess of $100bn despite their shortcomings. Affimer technology has been designed to address many of these negative performance issues, principally; the time taken to generate new antibodies, the reliance on an animal’s immune response, poor specificity in many cases, and batch to batch variability. Affimer technology is based on a small protein that can be quickly generated to bind with high specificity and affinity to a wide range of protein targets.
Avacta has a pre-clinical biotech development programme with an in-house focus on immuno-oncology as well as partnered development programmes. Avacta is commercialising non-therapeutic Affimer reagents through licensing to developers of life sciences research tools and diagnostics.
To register for news alerts by email go to www.avacta.com/investor-news-email-alerts
About Selexis SA
Selexis SA, a JSR Life Sciences Company, is the global leader in cell line development with best-in-class modular technology and highly specialized solutions that enable the life sciences industry to rapidly discover, develop and commercialize innovative medicines and vaccines. Our global partners are utilizing Selexis technologies to advance more than 121 drug products in clinical development and the manufacture of five commercial products. As part of a comprehensive drug development process, the Company’s technologies shorten development timelines and reduce manufacturing risks. JSR’s CDMO service offering leverages the full capabilities of Selexis’ proprietary SUREtechnology Platform™ to offer an end-to-end solution to the industry.
Selexis’ SUREtechnology Platform is based on Selexis SGE® (Selexis Genetic Elements) — novel human DNA-based elements that control the dynamic organization of chromatin across mammalian cells. These elements increase transcription rates of transgenes by rendering the expression cassette independent of the locus of integration and thus allowing higher and more stable expression of any recombinant proteins. SUREtechnology improves the way cells are used in the discovery, development and manufacturing of recombinant proteins and immune checkpoint inhibitors.
More information is available at www.selexis.com.
– Web www.selexis.com
– LinkedIn www.linkedin.com/company/selexis-sa
– Twitter www.twitter.com/SelexisSA
– Facebook www.facebook.com/SelexisSA
Record changed: 2023-06-05 |
Advertisement
More documents for JSR Corporation (Group)
- [1] KBI Biopharma, Inc.. (4/15/24). "Press Release: KBI Biopharma Appoints Jean-Baptiste Agnus as Chief Business Officer". Durham, NC....
- [2] Crown Bioscience, Inc.. (4/4/23). "Press Release: Crown Bioscience Announces Transaction Closing of Indivumed’s Service Business and Supporting Biobank". San Diego, CA....
- [3] Indivumed GmbH. (1/25/23). "Press Release: Crown Bioscience to Acquire Indivumed’s Service Business and Supporting Biobank". San Diego, CA & Hamburg....
- [4] Selexis S.A.. (5/2/22). "Press Release: JSR Appoints Veteran Biotech and CDMO Leader Mark W. Womack to Lead KBI Biopharma and Selexis SA". Sunnyvale, CA....
- [5] Selexis S.A.. (3/18/21). "Press Release: SpyBiotech Licenses Selexis Best-in-Class Cell Line Development Technologies to Advance Human Cytomegalovirus VLP Vaccine Program". Geneva....
- [6] Selexis S.A.. (10/20/20). "Press Release: JSR Life Sciences Expands Its European Gene-to-GMP Biologics Manufacturing Facilities for Selexis and KBI Biopharma in Geneva, Switzerland". Sunnyvale, CA....
- [7] Selexis S.A.. (10/16/20). "Press Release: Selexis Names Biopharmaceutical Executive Dirk Lange as New Chief Executive Officer". Geneva....
- [8] Selexis S.A.. (1/9/20). "Press Release: Selexis Promotes Dr. Yemi Onakunle to Chief Business Officer". Geneva....
- [9] Selexis S.A.. (3/28/19). "Press Release: Selexis Bolsters Business Development Team to Support Expanding Base of Partners Relying on Its SUREtechnology to Advance Complex Biologics and Vaccines". Geneva....
- [10] Selexis S.A.. (1/9/19). "Press Release: Selexis Expands Strategic Immuno-Oncology Alliance with Agenus". Geneva....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top